HAOMIAO TECHNOLOGY
831856
Anhui Bossco Environmental Protection Technology
300422
MH Robot & Automation
301199
Fibocom Wireless Inc.
300638
Allwinner Technology
300458
CN Stock MarketDetailed Quotes
002198 Guangdong Jiaying Pharmaceutical
- 6.92
- -0.06-0.86%
Noon Break Jan 21 11:30 CST
3.51BMarket Cap288.33P/E (TTM)
7.04High6.84Low41.62KlotVolume7.00Open6.98Pre Close28.81MTurnover0.82%Turnover Ratio101.76P/E (Static)507.51MShares9.3052wk High4.74P/B3.51BFloat Cap4.6252wk Low7.68Limit Up507.48MShs Float20.79Historical High6.28Limit Down2.87%Amplitude1.02Historical Low0.05Dividend TTM6.92Avg Price31.84KlotAsk0.72%Div YieldTTM100Lot Size9.42KlotBid
Guangdong Jiaying Pharmaceutical News
The seasonal influenza A has entered the epidemic period, and the sales of related Chinese Patent Medicine products have significantly increased.
① Recently, the positive rate of influenza virus has significantly increased, with over 99% being type A influenza. Market data shows a clear increase in the demand for various Traditional Chinese Medicine cold medicine products. ② Today, stock prices of several listed companies in the Traditional Chinese Medicine Industry, such as Shanxi Zhendong Pharmaceutical, Hainan Huluwa Pharmaceutical Group, and Zhongsheng Pharmaceutical, have reached the daily limit, with the Traditional Chinese Medicine Sector overall rising, and the Traditional Chinese Medicine 50 ETF increasing by 3.21%.
Guangdong Jiaying Pharmaceutical (002198.SZ): Share buyback has not yet been implemented.
Gelonghui, January 2nd丨Guangdong Jiaying Pharmaceutical (002198.SZ) announced that as of December 31, 2024, the company has not implemented a share buyback.
Jiaying Pharmaceutical to Buy Back Up to 132 Million Yuan of Shares
Guangdong Jiaying Pharmaceutical (002198.SZ): Plans to launch the 2024 employee stock ownership plan with a total fundraising amount not exceeding 60.615 million yuan.
On December 13, Gelonghui announced that Guangdong Jiaying Pharmaceutical (002198.SZ) has released a draft for the 2024 employee stock ownership plan. This plan aims to raise a total of no more than 60.615 million yuan, with each unit valued at 1 yuan, reserving 11.8536 million units. The upper limit for the number of units in this employee stock ownership plan is 60.615 million units, and the final total amount raised will be based on the actual fundraising total. The stocks for this employee stock ownership plan are sourced from the company's repurchase of Guangdong Jiaying Pharmaceutical A-share common stocks from the secondary market, and the number of stocks intended to be held in this plan is not specified.
There's Reason For Concern Over Guangdong Jiaying Pharmaceutical Co., Ltd's (SZSE:002198) Massive 26% Price Jump
Jiaying Pharmaceutical: Report for the third quarter of 2024
Guangdong Jiaying Pharmaceutical (002198.SZ): The net income for the first three quarters was 2.8733 million yuan, a year-on-year decrease of 88.46%.
Jiaying Pharmaceutical (002198.SZ) announced its third quarter report for 2024 on October 30th. The company achieved revenue of 0.26 billion yuan in the first three quarters of the year, a decrease of 31.18% year-on-year; the net income attributable to shareholders of the listed company was 2.8733 million yuan, a decrease of 88.46% year-on-year; the net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was -1.879 million yuan; basic earnings per share were 0.0057 yuan.
Guangdong Jiaying Pharmaceutical (002198.SZ): Orient, a shareholder owning more than 5% of the shares, plans to reduce its shareholding by no more than 1% of the company's shares.
Guangdong Jiaying Pharmaceutical (002198.SZ) announced on October 16 that shareholder Orient currently holds 57,223,000 shares of the company (accounting for 11.28% of the total share capital). Orient plans to reduce its shareholding by 5,075,098 shares (not exceeding 1% of the total share capital) through centralized competitive bidding trading within three months after fifteen trading days from the date of this shareholding reduction plan announcement.
Guangdong Jiaying Pharmaceutical Co., Ltd's (SZSE:002198) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?
Jiaying Pharmaceuticals: Semi-Annual Report 2024
Jiaying Pharmaceutical: 2024 Semi-Annual Report Summary
Guangdong Jiaying Pharmaceutical (002198.SZ): the net income in the first half of the year was 5.6677 million yuan, a year-on-year decrease of 68.94%.
Guangdong Jiaying Pharmaceutical (002198.SZ) announced its semi-annual report for 2024, with total operating revenue of 0.18 billion yuan, a decrease of 30.00% compared to the same period last year; net income attributable to shareholders of the listed company was 5.6677 million yuan, a decrease of 68.94% compared to the same period last year; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 1.1626 million yuan, a decrease of 93.07% compared to the same period last year; basic earnings per share of 0.0112 yuan.
Guangdong Jiaying Pharmaceutical (002198.SZ) released its half-year performance with a net income of 5.6677 million yuan, a decrease of 68.94%.
Guangdong Jiaying Pharmaceutical (002198.SZ) released its 2024 interim report, during the reporting period, the company achieved revenue...
By August 9, 2024, the number of shareholders of Guangdong Jiaying Pharmaceutical (002198.SZ) was 22,367.
Guangdong Jiaying Pharmaceutical (002198.SZ) stated on the investor interaction platform on August 12 that as of August 9, 2024, according to the shareholder list issued by China Clearing, the number of shareholders of the company is 22,367.
The function and indication of Guangdong Jiaying Pharmaceutical (002198.SZ) Double-Throat Wind-Dispersing Granules are clearing heat and detoxifying, reducing swelling and benefiting the throat.
Guangdong Jiaying Pharmaceutical (002198.SZ) stated on the investor interaction platform on July 17 that the dual-purpose throat and wind dispersal produced by the company has the following functions: clearing heat and detoxifying, reducing swelling and soothing the throat. It is used for throat and mouth ulcers, gum swelling and pain, sinusitis, skin ulcers and other conditions caused by lung and stomach fever and toxicity.
As of July 10th, Guangdong Jiaying Pharmaceutical (002198.SZ) had a total of 22,404 shareholders.
On July 12th, Gelunhui reported that Guangdong Jiaying Pharmaceutical (002198.SZ) stated on the investor interaction platform that as of July 10, 2024, according to the shareholder roster issued by the China Securities Depository and Clearing Co., Ltd., the company has 22,404 shareholders.
Subdued Growth No Barrier To Guangdong Jiaying Pharmaceutical Co., Ltd's (SZSE:002198) Price
Guangdong Jiaying Pharmaceutical: Guangdong Jiaying Pharmaceutical Co., Ltd.'s performance forecast for the first half of 2024.
Guangdong Jiaying Pharmaceutical (002198.SZ) issued a profit warning, with a projected net income of 46-58 million yuan, a year-on-year decrease of 68%-75%.
Jiaying Pharmaceutical (002198.SZ) announced its performance forecast for the first half of 2024, with an expected net income attributable to shareholders of the listed company of 4.6 million yuan to 5.8 million yuan, a year-on-year decrease of 68%-75%. After deducting non-recurring gains and losses, the net income is expected to be 0.8 million yuan to 1.2 million yuan, a year-on-year decrease of 93%-95%. In the first half of 2024, in response to the various challenges facing the company's operation, the company actively maintained the market sales of its leading products and worked to maintain market share. At the same time, the company made every effort to develop the market sales of potential exclusive varieties and relied on existing pharmaceutical products.
Guangdong Jiaying Pharmaceutical (002198.SZ) plans to distribute 0.5 yuan per 10 shares on June 21 for ex-rights and ex-dividends.
Jiaying Pharmaceutical (002198.SZ) announced that it plans to distribute an annual equity of 0.5 yuan (tax included) per 10 shares to all shareholders in 2023. The ex-rights and ex-dividend date is June 21, 2024.
